HDL and LDL: Potential New Players in Breast Cancer Development
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality in women. The identification of risk factors can improve prevention of cancer, and obesity and hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work, we review the progress to date in research on the potential role of the main cholesterol transporters, low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although some studies have failed to find associations between lipoproteins and breast cancer, some large clinical studies have demonstrated a direct association between LDL cholesterol levels and breast cancer risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast cancer cells and experimental mouse models of breast cancer have demonstrated an important role for cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate different inflammation-related pathways, thereby enhancing cell proliferation and migration and inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“Statins are inhibitors of the enzyme hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR), which catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of cholesterol synthesis [105].”
BackgroundSpontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237 · cited 1×
“The absence of apoE leads to the accumulation of cholesterol and triglycerides in plasma [42].”
BackgroundMiettinen, T. A., Puska, P., Gylling, H., Vanhanen, H., & Vartiainen, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332002 · Cited by 739
Baek, A. E., Yu, Y.-R. A., He, S., Wardell, S. E., Chang, C.-Y., Kwon, S., Pillai, R. V., McDowell, H. B., Thompson, J. W., Dubois, L. G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00910-z · Cited by 427 · cited 2×
“27-HC also hastened myeloid immune cell functions, as it was found that this oxysterol increased the number of polymorphonuclear neutrophils and γδ T cells as well as decreased cytotoxic CD8+ T cells within tumors and metastatic lesions [53].”
BackgroundStatin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387 · cited 1×
“[125] 2011 Prospective 18,769 Significant reduction in breast cancer recurrence among patients using simvastatin after 10 y of follow up (adjusted HR = 0.”
BackgroundTargeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model
Alikhani, N., Ferguson, R. D., Novosyadlyy, R., Gallagher, E. J., Scheinman, E. J., Yakar, S., & LeRoith, D. (2013) · Oncogene · doi:10.1038/onc.2012.113 · Cited by 146 · cited 3×
“The role of dyslipidemia in breast cancer growth and metastasis was also explored in hypercholesterolemic apolipoprotein E knockout mice (apoE–/–) fed an HFHC diet and injected with non-metastatic Met-1 and metastatic Mvt-1 mammary cancer cells derived from PyMT mice and c-Myc/vegf tumor explants, respectively [41].”
BackgroundMethodInfluentialHypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors In Vivo
Pelton, K., Coticchia, C. M., Curatolo, A. S., Schaffner, C. P., Zurakowski, D., Solomon, K. R., & Moses, M. A. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.03.006 · Cited by 109
Kimbung, S., Lettiero, B., Feldt, M., Bosch, A., & Borgquist, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10746 · Cited by 79
Cited by
Ren, L., Yi, J., Li, W., Zheng, X., Liu, J., Wang, J., & Du, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2587 · Cited by 145
Metadata
- Authors
- Cedó, L., Reddy, S. T., Mato, E., Blanco-Vaca, F., & Escolà-Gil, J. C.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-06-14
- Volume
- 8
- Issue
- 6
- Pages
- 853
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2952346286
- Cited by
- 172
- References
- 9
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.